Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.

In an approach to overcome biological barriers mediated by P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A), a series of stereoisomeric valine-valine prodrugs of saquinavir (SQV) were synthesized and investigated with respect to affinity for efflux pump P-gp, and resistance to oxidative and hydrolytic enzymes. Cellular uptake and bidirectional transport in Caco-2 cells indicated that all peptide SQV conjugates can bypass P-gp-mediated efflux significantly, regardless of stereochemistry in promoieties. In comparison with D-configuration, L-configuration was favored for the interaction between prodrugs and rat hepatic CYP3A enzymes, and resulted in a relatively rapid clearance by CYP3A. Elimination half-life of SQV in rat liver microsomes was prolonged dramatically by sevenfold to 40-fold because of the prodrug modification with the rank order of D-valine-D-valine-SQV > D-valine-L-valine-SQV > L-valine-D-valine-SQV > L-valine-L-valine-SQV > D-valine-SQV > L-valine-SQV > SQV. Results of hydrolysis studies performed in rat intestinal homogenates and plasma indicated that prodrugs attached with D-valine exhibited significantly reduced biodegradation. In conclusion, the enhanced transepithelial accumulation and enzymatic stability observed by SQV peptide prodrug modification are found to be stereoselective. Specific stereoisomeric dipeptide prodrugs with optimized metabolic stability can be employed to improve oral bioavailability of SQV.

[1]  D. Figgitt,et al.  Saquinavir Soft-Gel Capsule , 2000, Drugs.

[2]  C. Perry,et al.  Saquinavir Soft-Gel Capsule Formulation , 1998, Drugs.

[3]  W. Haefeli,et al.  Impact of drug transporters on cellular resistance towards saquinavir and darunavir. , 2010, The Journal of antimicrobial chemotherapy.

[4]  H. Christian,et al.  The apical (hPepT1) and basolateral peptide transport systems of Caco-2 cells are regulated by AMP-activated protein kinase , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[5]  J. Turgeon,et al.  Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. , 2010, Drug metabolism letters.

[6]  J. V. van Eijkeren,et al.  Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  A. Mitra,et al.  Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. , 2008, International journal of pharmaceutics.

[8]  J. Schellens,et al.  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice , 2008, Molecular Cancer Therapeutics.

[9]  A. Mitra,et al.  Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. , 2008, International journal of pharmaceutics.

[10]  J. Houston,et al.  Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir , 2008, Drug Metabolism and Disposition.

[11]  B. Vig,et al.  Enhanced Absorption and Growth Inhibition with Amino Acid Monoester Prodrugs of Floxuridine by Targeting hPEPT1 Transporters , 2008, Molecules.

[12]  P. Sinko,et al.  Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats , 2008, Drug Metabolism and Disposition.

[13]  A. Mitra,et al.  Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. , 2007, International journal of pharmaceutics.

[14]  Y. Kato,et al.  Functional Expression of Stereoselective Metabolism of Cephalexin by Exogenous Transfection of Oligopeptide Transporter PEPT1 , 2007, Drug Metabolism and Disposition.

[15]  A. Mitra,et al.  MDR- and CYP3A4-Mediated Drug–Drug Interactions , 2006, Journal of Neuroimmune Pharmacology.

[16]  J Brian Houston,et al.  In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. , 2006, Biochemical pharmacology.

[17]  A. Mitra,et al.  Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[18]  S. Majumdar,et al.  Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. , 2005, International journal of pharmaceutics.

[19]  J. Clement,et al.  Serum carboxylesterase activity in various strains of rats: sensitivity to inhibition by CBDP (2-/o-cresyl/4H∶1∶3∶2-benzodioxaphosphorin-2-oxide) , 2005, Archives of Toxicology.

[20]  M. Okuda,et al.  Efflux properties of basolateral peptide transporter in human intestinal cell line Caco-2 , 2004, Pflügers Archiv.

[21]  R. Borchardt,et al.  Metabolism, Uptake, and Transepithelial Transport of the Diastereomers of Val-Val in the Human Intestinal Cell Line, Caco-2 , 1996, Pharmaceutical Research.

[22]  S. Frokjaer,et al.  Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  C. Wagner,et al.  Pharmacokinetics of Amino Acid Phosphoramidate Monoesters of Zidovudine in Rats , 2002, Antimicrobial Agents and Chemotherapy.

[24]  D. Back,et al.  CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[26]  B. Poolman,et al.  Kinetics and Substrate Specificity of Membrane-Reconstituted Peptide Transporter DtpT ofLactococcus lactis , 2000, Journal of bacteriology.

[27]  H. Saito,et al.  Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  P. Sinko,et al.  Oral absorption of the HIV protease inhibitors: a current update. , 1999, Advanced drug delivery reviews.

[29]  J. Silverman,et al.  Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.

[30]  C. Decker,et al.  Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. , 1998, Journal of pharmaceutical sciences.

[31]  J. Beijnen,et al.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.

[32]  M. E. Fitzsimmons,et al.  Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[33]  D. Faulds,et al.  Saquinavir , 1996, Drugs.

[34]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[35]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[36]  J. O'grady,et al.  Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. , 1996, The Journal of antimicrobial chemotherapy.

[37]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[38]  V. Ganapathy,et al.  Differential Recognition of β-Lactam Antibiotics by Intestinal and Renal Peptide Transporters, PEPT 1 and PEPT 2 (*) , 1995, The Journal of Biological Chemistry.

[39]  J. R. Bronk,et al.  Dipeptide transport and hydrolysis in isolated loops of rat small intestine: effects of stereospecificity. , 1995, The Journal of physiology.

[40]  V. Stella,et al.  Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. , 1994, Drug metabolism and disposition: the biological fate of chemicals.